About Shanghai Medicilon Inc. Company

The company is a professional biomedical pre-clinical comprehensive research and development service CRO, providing a full range of one-stop new drug research and development services that meet domestic and international application standards for pharmaceutical companies and research institutions around the world. The company's main business is to provide pharmaceutical research and development services for drug discovery, pharmaceutical research, and pre-clinical research to pharmaceutical companies and research institutes through R&D technology platforms. The company's services cover the whole process of pre-clinical drug research, mainly including drug discovery, pharmaceutical research and pre-clinical research. Drug discovery R&D service projects include protein target verification, structural biology, chemical synthesis, and compound activity screening and optimization; pharmaceutical research includes research on raw materials and formulation processes, quality standards and stability studies; and pre-clinical research includes pharmacodynamics, pharmacokinetics, and toxicological safety evaluation studies. Corporate honors: AAALAC certification, national pharmaceutical clinical research and development base, NMPA Pharmaceutical Safety Assessment GLP laboratory, life science base, “2022 Continuous Investment Value 'Star' Company”, “2022 Listed Company Enterprise Number 'Investment Elite Award'”, “Golden Horse Award - 2022 Best Pre-clinical CRO/CDMO Company (Mature)”, “3rd Pharmaceutical Innovation World Award 'Top 10 Pharmaceutical Innovation Service Organizations' of the Year”, “2023 Top 20 Chinese Pharmaceutical Companies”, etc. Honors include “2023 China's Top 20 Pharmaceutical CRO Companies”, “Top 10 Most Influential CRO Companies in the 2023 China Biomedical Industry Value List”, “Top 50 Chinese Pharmaceutical Research and Development”, and “2023 Golden Bull Science and Technology Innovation Award”.